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Background
Lifetime exposure to circulating steroid hormones via the 
number of menstrual cycles, menopausal hormone 
therapy, and perhaps pregnancy all increase breast cancer 
risk [1]. Th  e details underlying this increased risk, 
however, have long remained elusive. Th  e  re-emergence 
of the cancer stem cell (CSC) theory since its original 
inception over a century ago [2] has popularized mammary 
stem cells (MaSCs) as putative cells of origin for breast 
cancers. Since the MaSCs reside within the steroid 
receptor-negative basal epithelial compartment [3], it 
was presumed that steroid hormone signaling would 
have little impact on their regulation. Th  is  presumption 
was despite earlier work demonstrating that estrogen 
receptor (ER)-positive and progesterone receptor (PR)-
positive luminal cells in the normal breast use a paracrine 
mechanism to instruct neighboring ER-negative/PR-
negative cells to proliferate [4]. Two seminal papers now 
uncover a critical role for steroid hormones in controlling 
both the number and the regenerative function of MaSCs 
in the normal murine mammary gland. Th  ese exciting 
ﬁ  ndings promise to revolutionize our perception of how 
the female sex steroid hormones regulate the diﬀ  er-
entiation state of the breast and inﬂ   uence the risk of 
breast disease [5,6].
The articles
Asselin-Labat and colleagues establish that steroid 
hormone deprivation via ovariectomized or aromatase-
deﬁ  cient mice signiﬁ  cantly reduces the ability of MaSCs 
(CD29hiCD24+) to repopulate a mammary gland in the 
cleared fat pad of syngeneic recipient mice [5]. A 
combination of 17β-estradiol plus progesterone, but not 
17β-estradiol or progesterone alone, in ovariectomized 
mice restores the repopulating frequency of MaSCs. 
Blockade of either 17β-estradiol (letrozole) or proges-
terone (RU486) did not aﬀ  ect MaSC numbers, but did 
reduce their repopulating ability and ductal outgrowth 
formation, respectively – indicating that MaSCs rely on 
the luminal compartment for func  tional signals. 
Interestingly, the hormonal state of the donor imprints its 
mark on the repopulating ability of MaSCs.
In a parallel article, Joshi and colleagues demonstrate 
that the MaSC population (CD29hiCD49fhiCD24+) ﬂ  uc  tu-
ates with the mouse estrous cycle [6]. Speciﬁ  cally, high 
serum progesterone levels at diestrous, or when given 
exoge  nously to ovariectomized mice, are respon  sible for 
the increase in MaSCs. Th  e authors propose that the 
major role of 17β-estradiol is to induce expression of PR, 
which mediates the progesterone-driven MaSC expan-
sion. MaSC proliferation is accompanied by increased 
apop  tosis, which assists in returning MaSC numbers to 
baseline levels after each cycle. Aged, noncycling mice 
have a static MaSC population, further underscoring 
hormonal involvement.
Both of these articles implicate paracrine signaling 
from the ER-positive/PR-positive luminal epithelial 
compart  ment in control of MaSC expansion [5,6]. RANK 
ligand, which is progesterone regulated [7], was identiﬁ  ed 
as a key paracrine factor involved in mediating MaSC 
division. Abolishing RANK signaling disrupted the ability 
of luminal cells to stimulate MaSC division [5], indicating 
that RANK ligand is at least one factor that transmits the 
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© 2010 BioMed Central Ltdhormonal signal. Th   e crux of these data is that the MaSC 
population is dynamic, not static, and is notably cued by 
the hormone state.
The viewpoint
Th  ese studies in the murine mammary gland will 
probably drive further research into the inﬂ  uence  of 
hormones on stem cells in humans, not only in the breast 
but in other tissues as well. Indeed, in the normal human 
breast, progesterone was recently found to increase the 
number of progenitor cells [8]. Th   e hormone-driven risk 
of breast cancer in women may be tied to the extent of 
expansion/retraction of the transformation-sensitive 
MaSC population.
Th   e discussed studies lead to the question of whether 
hormones regulate a CSC component in human breast 
cancers. Breast CSCs appear to be steroid receptor-
negative [9], and in luminal tumors, at least, could be 
regulated by surrounding ER-positive/PR-positive cancer 
cells. Indeed, xenograft tumors grown from breast cancer 
cell lines have an increased number of cells with an ER-
negative/PR-negative CSC phenotype when grown with 
both 17β-estradiol and progesterone, compared with 
17β-estradiol alone [10]. Th   is suggests that progesterone 
can expand stem cells in malignant tissue as well as in 
normal tissue [8]. It is possible that the quiescent stem 
cell popu  la  tion in postmenopausal women could be 
mobil  ized during progestin-containing hormone therapies, 
account  ing for the higher incidence of breast cancer in such 
cases. Th  e fact that PR is critical for murine mammary 
tumorigenesis [11] further emphasizes a role for 
progesterone signaling in human breast tumor formation.
Th  e  ﬂ  uctuation in MaSC numbers in the normal gland 
suggests a potential plasticity in breast CSC numbers. 
Th   e observed stasis returned after cycles, pregnancy, and 
aging in the models may not be complete in some 
women, leading to higher risk of mutation and disease. 
Individual variability in the number of MaSCs combined 
with genetic inﬂ  uences probably aﬀ  ects susceptibility to 
breast cancer. An expanded CSC population could also 
adversely aﬀ  ect treatment response or risk of recurrence.
It is of note that MaSCs are dependent on a healthy, 
functioning luminal cell compartment. In breast cancer, 
antiestrogen therapies that attack the luminal population 
could indirectly ablate CSCs. In endocrine-resistant 
tumors, CSCs could have lost their dependence on the 
luminal ER-positive/PR-positive cells. Lim and colleagues 
suggest that the potential cell of origin of basal steroid 
receptor-negative cancers is a luminal progenitor [12], 
normally reliant on steroid hormone signaling [5]. Th  ese 
progenitors may lose their hormone dependence early in 
transformation. Deciphering a potential luminal cell/
stem cell interaction in breast cancer may divulge new 
targets for treatment of this disease.
In summary, the two proﬁ   led articles unearth a new 
paramount role for a steroid-sensitive luminal cell niche in 
regulating MaSCs. If the latter are indeed the cells of origin 
for breast cancers, then ovarian hormones do control the 
degree of risk for this disease. Progesterone has a historical 
reputation as a diﬀ  erentiating hormone, and it may well 
be, at least in luminal cells, destined towards terminal 
diﬀ  erentiation. However, progesterone is evi  dently even 
more important than 17β-estradiol in regulating stem cell 
populations, thereby altering our percep  tion of its role in 
both the normal breast and breast cancer.
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